Browsing "Comunicações em Eventos - LIM/24" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 40 to 59 of 577 < previous   next >
Issue DateTitleAuthor(s)
2012C-myc expression in dysplasias and carcinomas developed in the tongue from galectin-3-deficient and wild-type mice challenged by 4NQOGONCALVES, G. J. M.; RAMOS, W. A.; CHAMMAS, R.; LOYOLA, A. M.; CARDOSO, S. V.; FARIA, P. R.
2020CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma.MUNHOZ, Rodrigo Ramella; CAMARGO, Veridiana Pires De; MARTA, Guilherme N.; MARTINS, Jade Cury; NARDO, Mirella; BARBOSA, Caroline Chaul; SOUZA, Carina Echer de; BARBOSA, Ingrid; RICCI, Herminia; MATTOS, Marcela Rodrigues de, et al
2019Cachexia in head and neck squamous cell carcinoma (HNSCC) patients (pts) after cisplatin-based chemoradiation (CRT): A cross-sectional study.CASTRO, Gilberto; NEVES, Willian das; RIVELLI, Thomas Giollo; SIMAO, Eduardo Furquim; MARTINS, Renata Eiras; KULCSAR, Marco Aurelio Vamondes
2014Calcitriol effects on breast cancer tumorgraftsKATAYAMA, Maria Lucia Hirata; FONSECA-FILHO, Victor Celso N.; LYRA, Eduardo Carneiro; MARIA, Durvanei Augusto; BASSO, Ricardo Alves; NONOGAKI, Suely; GUERRA, Juliana Mariotti; MAISTRO, Simone; GOES, Joao Carlos Sampaio; FOLGUEIRA, Maria Aparecida A. Koike
2014CAN MRI PREDICT PATHOLOGIC RESPONSE OF RECTAL CANCER AFTER NEOADJUVANT TREATMENT?NAHAS, C.; NAHAS, S.; ORTEGA, C.; AZAMBUJA, R.; JOAQUIM, H.; MARQUES, C.; RIBEIRO, U.; BUSTAMANTE, L. L.; HOFF, L. P.; CECCONELLO, I.
2018Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?MUNDIM, F.; FRANCO, A.; INFANTE, K.; NETO, J.; BRENTANI, M. M.; FACINA, G.; WAITZBERG, A.
2022Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial.TAN, Daniel S.; FELIP, Enriqueta; CASTRO, Gilberto; SOLOMON, Benjamin J.; GREYSTOKE, Alastair; CHO, Byoungchul; COBO, Manuel; KIM, Tae Min; GANGULY, Sandip; CARCERENY, Enric, et al
2023Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1TAN, D. S.; FELIP, E.; CASTRO JUNIOR, G. de; SOLOMON, B. J.; GREYSTOKE, A.; CHO, B. C.; COBO, M.; KIM, T. M.; GANGULY, S.; WU, J., et al
2019Cancer driver genes in prostate cancer from young men.MAISTRO, Simone; XAVIER, Camila dos Santos; SERIO, Pedro Adolpho M. P.; KATAYAMA, Maria Lucia Hirata; ROELA, Rosimeire Aparecida; FOLGUEIRA, Maria A. A. Koike
2017Cancer Immunotherapy Mediated by Combined p19Arf and Interferon-Beta Gene Transfer: Evidence from Vaccine and In Situ Gene Therapy ModelsSTRAUSS, Bryan E.; MEDRANO, Ruan F. V.; CATANI, Joao Paulo P.; HUNGER, Aline
2013Cancer patients with ECOG-PS higher than 1: Who are those who benefit of palliative chemotherapy?CAIRES-LIMA, Rafael; PROTASIO, Bruno Mendonca; CAIRES, Inacelli Queiroz de Souza; ROCHA, Lucila Soares Da Silva; OLIVEIRA, Julia Andrade De; GUERRA, Raquel Bezerra; MAK, Milena Perez; HOFF, Paulo M.; CASTRO, Gilberto
2013Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome.KUPFER, Sonia; GUINDALINI, Rodrigo Santa Cruz; GULDEN, Cassandra; UKAEGBU, Chinedu I.; KOEPPE, Erika; CONRAD, Peggy; HAMPEL, Heather; STOFFEL, Elena Martinez; SYNGAL, Sapna; OLOPADE, Olufunmilayo I.
2019CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)PAZ-ARES, L.; GARON, E. B.; ARDIZZONI, A.; BARLESI, F.; CHO, B. C.; CASTRO JUNIOR, G. de; MARCHI, P. De; FELIP, E.; GOTO, Y.; GREYSTOKE, A., et al
2019The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).PAZ-ARES, Luis G.; GARON, Edward B.; ARDIZZONI, Andrea; BARLESI, Fabrice; CHO, Byoung Chul; CASTRO, Gilberto; MARCHI, Pedro De; FELIP, Enriqueta; GOTO, Yasushi; GREYSTOKE, Alastair, et al
2020The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC)GARON, E. B.; ARDIZZONI, A.; BARLESI, F.; CHO, B. C.; CASTRO, G. De; FELIP, E.; GOTO, Y.; GREYSTOKE, A.; LU, S.; LIM, D. W. -T., et al
2019CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLCTAN, D. S. W.; KIM, T. M.; SOLOMON, B. J.; TAN, W. L.; YU, C-J.; GEATER, S.; CASTRO JR., G. De; GREYSTOKE, A.; FELIP, E.; JOHNSON, B. E., et al
2020Canopy-1: Phase 3 Study of Canakinumab/PlaceboFELIP, E.; JR, G. Castro; GREYSTOKE, A.; SOLOMON, B.; TAN, D. S. W.; GROHE, C.; PASSOS, V. Q.; DEUDON, S.; LOUVEAU, A. L.; ARTICUS, K., et al
2019CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC PtsFELIP, E.; CASTRO, G.; GREYSTOKE, A.; SOLOMON, B.; TAN, D.; PASSOS, V.; DEUDON, S.; LOUVEAU, A.; JOHNSON, B.
2019CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus PlatinumChemotherapy in Untreated Stage IIIB-IV NSCLC PatientsJOHNSON, B. E.; CASTRO, G. D.; GREYSTOKE, A.; SOLOMON, B.; TAN, D. S. W.; PASSOS, V.; DEUDON, S.; LOUVEAU, A. L.; FELIP, E.
2020CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLCGROHE, C.; JOHNSON, B. E.; KIM, T. M.; HILTERMANN, T. J. N.; BARLESI, F.; GOTO, Y.; GUNNARSSON, O.; OVERBECK, T.; REGUART, N.; WERMKE, M., et al
Showing results 40 to 59 of 577 < previous   next >